|
Asthma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
CCL20 treatment of ALI-cultured CALU-3 and primary airway epithelial cells induced mucus production, while CCL20 levels in sputum were associated with increased levels of CMH in asthmatic patients.Elevated CCL20 production by ASMCs, possibly resulting from dysregulated expression of the anti-inflammatory miR-146a-5p, may contribute to enhanced mucus production in asthma.
|
29946002 |
2018 |
|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
In our validation of this technology, we successfully identified oxysterol binding protein-like 5 and calumenin as potential biomarkers related to metastasis in lung cancer, annexin A4 as a potential biomarker related to cisplatin resistance in malignant mesothelioma, and Eph receptor A10 as a potential therapeutic target in breast cancer, including refractory breast cancer.
|
29709904 |
2018 |
|
Filariasis
|
0.010 |
Biomarker
|
disease |
BEFREE |
A Ca<sup>2+</sup> binding protein, calumenin, was identified as a novel and nematode-specific drug target for filariasis, due to its involvement in fertility and cuticle development in nematodes.
|
30428563 |
2018 |
|
Secondary malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
In our validation of this technology, we successfully identified oxysterol binding protein-like 5 and calumenin as potential biomarkers related to metastasis in lung cancer, annexin A4 as a potential biomarker related to cisplatin resistance in malignant mesothelioma, and Eph receptor A10 as a potential therapeutic target in breast cancer, including refractory breast cancer.
|
29709904 |
2018 |
|
Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In our validation of this technology, we successfully identified oxysterol binding protein-like 5 and calumenin as potential biomarkers related to metastasis in lung cancer, annexin A4 as a potential biomarker related to cisplatin resistance in malignant mesothelioma, and Eph receptor A10 as a potential therapeutic target in breast cancer, including refractory breast cancer.
|
29709904 |
2018 |
|
Cardiomyopathy, Hypertrophic, Familial
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
CCL20 treatment of ALI-cultured CALU-3 and primary airway epithelial cells induced mucus production, while CCL20 levels in sputum were associated with increased levels of CMH in asthmatic patients.Elevated CCL20 production by ASMCs, possibly resulting from dysregulated expression of the anti-inflammatory miR-146a-5p, may contribute to enhanced mucus production in asthma.
|
29946002 |
2018 |
|
Refractory Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In our validation of this technology, we successfully identified oxysterol binding protein-like 5 and calumenin as potential biomarkers related to metastasis in lung cancer, annexin A4 as a potential biomarker related to cisplatin resistance in malignant mesothelioma, and Eph receptor A10 as a potential therapeutic target in breast cancer, including refractory breast cancer.
|
29709904 |
2018 |
|
Malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
The CALU-1 lung cancer cells were cultured in 3D collagen to mimic in vivo tissue.
|
28556307 |
2017 |
|
Primary malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
The CALU-1 lung cancer cells were cultured in 3D collagen to mimic in vivo tissue.
|
28556307 |
2017 |
|
Neoplasm Metastasis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Calumenin and fibulin-1 are two extracellular proteins that synergistically inhibit cell migration and tumor metastasis, and could potentially be served as targets for pharmacological research of anti-metastatic drugs.
|
25976680 |
2015 |
|
Vascular calcification
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
CALU polymorphism A29809G affects calumenin availability involving vascular calcification.
|
25823396 |
2015 |
|
Secondary Neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
Calumenin and fibulin-1 are two extracellular proteins that synergistically inhibit cell migration and tumor metastasis, and could potentially be served as targets for pharmacological research of anti-metastatic drugs.
|
25976680 |
2015 |
|
Cystic Fibrosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Fluorescence microscopy based imaging analysis also revealed altered trafficking of calumenin in bronchial cells expressing F508del-CFTR, indicating its direct role in the pathophysiology of CF.
|
25120007 |
2014 |
|
Malignant tumor of colon
|
0.010 |
Biomarker
|
disease |
BEFREE |
We have identified LTBP2, CDH11, OLFML3, and FSTL1 as selective biomarkers of cancer stroma, and CALU and CDH11 as candidate stromal biomarkers of prognostic significance in colon cancer.
|
24025712 |
2013 |
|
Colon Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We have identified LTBP2, CDH11, OLFML3, and FSTL1 as selective biomarkers of cancer stroma, and CALU and CDH11 as candidate stromal biomarkers of prognostic significance in colon cancer.
|
24025712 |
2013 |
|
Arteriosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Calumenin (CALU), a protein regulating proteins involved in coagulation and arterial calcification also has extracellular functions related to atherosclerosis.
|
20673165 |
2010 |
|
Atherosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Calumenin (CALU), a protein regulating proteins involved in coagulation and arterial calcification also has extracellular functions related to atherosclerosis.
|
20673165 |
2010 |
|
Atherothrombosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
CALU A29809G polymorphism in coronary atherothrombosis: Implications for coronary calcification and prognosis.
|
20673165 |
2010 |
|
Ischemic stroke
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
This study sought to determine the contribution of four genes, vitamin K epoxide reductase (VKORC1), gamma-glutamyl carboxylase (GGCX), calumenin (CALU), and cytochrome P450 2C9 (CYP2C9) to the warfarin maintenance dose required in Japanese patients following ischemic stroke.
|
17049586 |
2007 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
CALU-3 is a human lung adenocarcinoma cell line that overexpresses p185. muMoAb-4D5 is a murine anti-p185 monoclonal immunoglobulin G1.
|
8893583 |
1996 |
|
Tumor necrosis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
While SK-OV-3 was unable to recruit human leukocytes and appeared to be barely infiltrated by murine CD45+ cells, CALU-3 appeared to be rapidly and heavily infiltrated by human leukocytes which induced tumor necrosis within 18-24 hr.
|
7665228 |
1995 |
|
Carcinoma of lung
|
0.020 |
Biomarker
|
disease |
BEFREE |
The CALU-1 lung cancer cells were cultured in 3D collagen to mimic in vivo tissue.
|
28556307 |
2017 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
CALU-6 tumor-bearing nu/nu mice (n=46) were evaluated in 3 therapeutic trials measuring FLT and FDG prediction of tumor response at 72 h following initiation of daily combination therapy with targeted agents, TRAIL (200 µg i.v.) and sorafenib (30 mg/kg i.p.) and compared to conventional chemotherapeutics cisplatin (3 mg/kg i.p.) and docetaxel (7.5 mg/kg i.p.).
|
21537838 |
2011 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Bortezomib significantly inhibited the growth of EGFR inhibitor-resistant CALU-3 cells which were established as subcutaneous tumor xenografts in athymic nude mice.
|
20619923 |
2011 |
|
Carcinoma of lung
|
0.020 |
Biomarker
|
disease |
BEFREE |
Two carcinoma cell lines, SK-OV-3 ovary carcinoma and CALU-3 lung carcinoma, were analyzed by reverse transcriptase-polymerase chain reaction (RT-PCR), immunofluorescence and ELISA for the expression and in vitro production of cytokines with chemotactic, proinflammatory and growth-stimulating activity.
|
7665228 |
1995 |